The City Planning Commission is currently reviewing an updated draft scope of work to expand the New York Blood Center’s Upper East Side headquarters. The commission will need to approve proposed amendments to the area’s existing zoning rules before the project can begin.
The proposals call for demolition of the existing New York Blood Center headquarters at 310 East 67th Street between First and Second Avenues. In its place, a new 16-story building would serve as the center’s base of operations with a total area of 596,200 square feet.
The commission will also need to sign off on an Environmental Impact Statement to assess the development’s potential affect on the area in regard to health and safety, shadows cast by the mid-rise building, infrastructure, displacement of business, and how the zoning changes could affect future developments.
If approved, the project team anticipates the creation of approximately 2,600 new on-site jobs and 3,000 additional jobs in the surrounding neighborhood as a result of the new building and hundreds of new employees. The total economic impact of the project is estimated at $1.1 billion in annual revenue.
As previously reported by YIMBY, Ennead Architects is responsible for design of the new building. The New York Blood Center’s will occupy the first through fifth floors. These levels will include a ground-floor blood donation center, state-of-the art research labs, office space, and administrative areas. Floors seven and above will be reserved for organizations affiliated with Longfellow Real Estate Partners, co-developer of the Center East campus expansion.
Additional activations will include collaborative work spaces, a café, meeting rooms, and conference areas.
“We believe deeply in the mission of New York Blood Center and that Center East can serve as the catalyst to generating a thriving life science ecosystem in New York City,” said Jamison Peschel, managing partner at Longfellow Real Estate Partners. “This is an incredible opportunity for NYBC and for New York to leverage the research capacity of world-class institutions and drive the commercialization of advances that will save lives.”